.png)
TL;DRAppropriate comparator therapy (zVT, zweckmäßige Vergleichstherapie) is the established therapy that the Gemeinsamer Bundesausschuss (G-BA) sets as the benchmark for a new medicine in the German early benefit assessment under §35a SGB V. A Zusatznutzen (added benefit) only exists relative to it.
Every new active substance entering the German market is assessed against something. That something is the zVT. It is not chosen by the manufacturer and it is not simply "the market leader": it is determined by the G-BA on the basis of §6 AM-NutzenV (Arzneimittel-Nutzenbewertungsverordnung), per approved indication and, where the label covers several patient groups, per subpopulation. The manufacturer then has to build its dossier on studies that compare its product against exactly that therapy. If the dossier compares against something else, the G-BA can rate the added benefit as not proven, regardless of how good the clinical data are in absolute terms.
The zVT is the most contested single point in the whole AMNOG procedure, because it works twice: once on the clinical verdict and once on the price.
On the clinical side, the comparator defines what "better" means. A new oncology drug measured against best supportive care faces a very different bar than the same drug measured against an active combination regimen. Since §6 Abs. 2 AM-NutzenV requires a therapy that is appropriate according to the generally recognised state of medical knowledge, preferably one with endpoint studies and proven in practical use, the G-BA tends towards well-documented standards rather than newest entrants.
On the price side, the effect is mechanical. Under §130b Abs. 1 SGB V the GKV-Spitzenverband negotiates the Erstattungsbetrag with the manufacturer on the basis of the G-BA benefit decision. §130b Abs. 3 SGB V then sets the guardrails (Leitplanken) explicitly against the annual therapy costs of the zVT: where no added benefit is shown and the comparator is under patent or data protection, the agreed amount must lead to annual therapy costs at least 10 percent below those of the zVT; where a generic comparator is available, the amount should not lead to higher annual therapy costs than the zVT. In practice, if a cheap generic is the comparator, the achievable price is capped hard before negotiation even begins. This is why manufacturers invest heavily in arguing the comparator, and why the zVT is the point at which market access is usually won or lost. For the wider procedure see frühe Nutzenbewertung, for the legislative frame AMNOG, and for the negotiated outcome Erstattungsbetrag.
The substantive rules sit in §6 AM-NutzenV. In sequence:
Manufacturers do not have to guess. Under §35a Abs. 7 SGB V the G-BA advises companies on the documents and studies to be submitted and specifically on the comparator therapy, so the zVT can be agreed in a Beratungsverfahren before the pivotal trial design is locked. Getting this wrong before Phase III is expensive and rarely fixable afterwards.
The three are routinely confused because all involve comparing medicines. They answer different questions.
| Concept | What it is | Who sets it | Legal basis | Effect |
|---|---|---|---|---|
| Appropriate comparator therapy (zVT) | The yardstick: the established therapy a new medicine is measured against | G-BA, per indication and subpopulation | §35a SGB V, §6 AM-NutzenV | Defines the evidence the dossier must deliver |
| Zusatznutzen | The result: extent and probability of added benefit measured against the zVT | G-BA decision after IQWiG assessment and hearing | §35a SGB V | Feeds directly into the price negotiation |
| Festbetragsgruppe | A group of pharmacologically or therapeutically comparable products sharing one reimbursement ceiling | G-BA forms the group, GKV-Spitzenverband sets the amount | §35 SGB V | Caps reimbursement for the whole group, not a benefit judgement |
Put simply: the zVT is the ruler, the Zusatznutzen is the measurement, and the Festbetragsgruppe is a separate price-capping instrument that operates on comparable products already on the market. A medicine with a recognised added benefit is as a rule not placed in a Festbetragsgruppe; it goes into an Erstattungsbetrag negotiation instead.
The zVT determination itself is a regulatory act. It is published in the G-BA Beschluss and its tragende Gründe, not in article master data. What downstream teams need alongside it is the product reality: which comparator products actually exist, in which pack sizes, at which prices, and whether they are currently available at all. That is where a consolidated data layer helps: annual therapy cost modelling for a candidate comparator needs current price and pack data per product, not a PDF.
Honest limitation: pharmazie.com does not carry the G-BA's zVT determination as a structured data field. The comparator itself, its subpopulation split and the reasoning behind it have to be read from the G-BA Beschluss. What the platform contributes is the product and price side of the calculation, per PZN and updated daily, so that annual therapy costs for a comparator can be modelled against current market data rather than reconstructed by hand.
